

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HANGZHOU TIGERMED CONSULTING CO., LTD.

杭州泰格醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3347)

**PROPOSED RE-ELECTION AND APPOINTMENTS OF DIRECTORS OF
THE SIXTH SESSION OF THE BOARD**

The term of office of the fifth session of the Board of Hangzhou Tigermed Consulting Co., Ltd. will soon expire. In accordance with relevant provisions of the Company Law and the Articles of Association, the sixth session of the Board shall comprise 7 Directors, including 1 employee director.

Upon the recommendation of the Nomination Committee, the Board has proposed: (1) the re-election of Dr. Ye Xiaoping, Ms. Cao Xiaochun and Mr. Wen Zengyu as executive Directors of the sixth session of the Board; (2) the re-election of Mr. Yuan Huagang and Ms. Liu Yuwen as independent non-executive Directors of the sixth session of the Board; and (3) the appointment of Mr. Siu, Paul Yu Hay as an independent non-executive Director of the sixth session of the Board. In accordance with the requirements of relevant laws, regulations and the Articles of Association, the above-mentioned proposed appointments of the Directors of the sixth session of the Board are subject to the approval by the Shareholders at the general meeting. The term of office of each of the above-mentioned Director candidates shall be valid for three years commencing from the date of consideration and approval by the general meeting of the Company.

The biographical details of the Director candidates proposed to be re-elected or appointed are set out below:

CANDIDATES FOR EXECUTIVE DIRECTORS

Dr. Ye Xiaoping (葉小平), aged 63, is the chairman of the Board, an executive Director and co-founder of our Company. Dr. Ye was appointed as the chairman of the Board and a Director since the incorporation of our Company in September 2010 and designated as an executive Director in April 2020. From September 2010 to April 2019, Dr. Ye served as the general manager of our Company. From March 2005 to September 2010, Dr. Ye served successively as manager, director and general manager at Hangzhou Tigermed Limited, the predecessor of our Company. Dr. Ye is primarily responsible for the overall strategic planning of the Group and supervising and overseeing the management of our business. Dr. Ye is the chairman of the Strategy Development Committee of our Company. Dr. Ye possesses extensive experience in biopharmaceutical R&D and strategic planning. Dr. Ye received his doctorate degree in immunology from University of Oxford in April 2001.

Dr. Ye served as a director of Dian Diagnostics Group Co., Ltd. (迪安診斷技術集團股份有限公司) (a company listed on the Shenzhen Stock Exchange with stock code: 300244) from September 2020 to December 2022 and Coland Holdings Limited (康聯控股有限公司) (a company listed on the Taiwan Stock Exchange with stock code: 4144, but ceased to be listed on the Taiwan Stock Exchange on October 30, 2020) since December 2010. He served as an independent non-executive director of HBM Holdings Limited (和鉑醫藥控股有限公司) (a company listed on the Stock Exchange with stock code: 2142) since December 2020. From October 2011 to January 2020, Dr. Ye served as a director of Shanghai Lide Biotech Co., Ltd. (上海立迪生物技術股份有限公司) (National Equities Exchange and Quotations stock code: 838848), the shares of which ceased to be listed on the National Equities Exchange and Quotations in April 2019.

As at the date of this announcement, Dr. Ye Xiaoping directly holds 177,239,541 of our A Shares, representing 20.58% of our total issued share capital of the Company. Dr. Ye Xiaoping and Ms. Cao Xiaochun entered into the Concert Agreement on June 9, 2010 and each of them is deemed to be interested in the A Shares that the other person is interested in under section 317 of the SFO. Ms. Cao Xiaochun holds 51,314,174 of our A Shares, representing 5.96% of our total issued share capital of our Company. Therefore, Dr. Ye Xiaoping and Ms. Cao Xiaochun are deemed to be interested in a total of 228,553,715 of our A Shares, representing 30.97% of the total number of A Shares of our Company and 26.54% of our total issued share capital.

Ms. Cao Xiaochun (曹曉春), aged 57, is an executive Director, co-founder and general manager. Ms. Cao was appointed as a deputy general manager in September 2010 and was later appointed as the general manager in April 2019. She was designated as an executive Director in April 2020. From September 17, 2021 to October 21, 2022, she served as the chief financial officer of the Company. From November 2010 to May 2019, Ms. Cao served as secretary to the Board of our Company. Ms. Cao served as executive director and director successively from January 2005 to September 2010 of Hangzhou Tigermed Limited, the predecessor of our Company. Ms. Cao is primarily responsible for overseeing the Group's operations and management. Ms. Cao is a member of the Remuneration and Evaluation Committee of our Company. Ms. Cao possesses extensive experience in biopharmaceutical R&D and business operations and management.

Ms. Cao received her bachelor's degree in traditional Chinese medicine and pharmacy from Zhejiang Chinese Medical University (浙江中醫藥大學) in July 1992, graduate certificate in medicine from Zhejiang University (浙江大學) in June 2003 and graduate certificate in business administration from Renmin University of China (中國人民大學) in June 2007. Ms. Cao was admitted as a licensed pharmacist in the PRC by the Office of Personnel of Zhejiang Province (浙江省人事廳) in October 2001 and a senior engineer in the PRC by the Office of Personnel of Zhejiang Province (浙江省人事廳) in December 2002.

As at the date of this announcement, Ms. Cao Xiaochun holds 51,314,174 of our A Shares, representing 5.96% of our total issued share capital of our Company. Dr. Ye Xiaoping and Ms. Cao Xiaochun entered into the Concert Agreement on June 9, 2010 and each of them is deemed to be interested in the A Shares that the other person is interested in under section 317 of the SFO. Dr. Ye Xiaoping directly holds 177,239,541 of our A Shares, representing 20.58% of our total issued share capital of the Company. Therefore, Dr. Ye Xiaoping and Ms. Cao Xiaochun are deemed to be interested in a total of 228,553,715 of our A Shares, representing 30.97% of the total number of A Shares of our Company and 26.54% of our total issued share capital.

Mr. Wen Zengyu (聞增玉), aged 46, joined the Company in March 2010 and is currently an executive Director, executive vice president and chief operating officer of the Company. Mr. Wen was appointed as an executive Director in May 2023. Mr. Wen has 19 years of experience in the pharmaceutical industry. Prior to joining the Group, Mr. Wen served as a statistician of APEX International Clinical Research Co., Ltd. from March 2004 to November 2004 and a senior statistician of Schering Plough Pharmaceutical Co., Ltd.* (先靈葆雅製藥有限公司) from December 2004 to February 2010.

Mr. Wen obtained his bachelor's degree in health service management from Weifang Medical University in July 2001 and a master's degree in epidemiology and hygienic statistics from Fudan University in June 2004.

Mr. Wen served as an executive director of Hangzhou Tigermed-IntelliPV Co., Ltd., Jiaxing Tigermed Data Management Co.,Ltd. and Tigermed Xinze Medical Technology (Jiaxing) Co., Ltd. (each a wholly-owned subsidiary of the Company) since July 2021, and served as an executive director of MacroStat (China) Clinical Research Co., Ltd. (a wholly-owned subsidiary of the Company) since August 2021.

CANDIDATES FOR INDEPENDENT NON-EXECUTIVE DIRECTORS

Mr. Yuan Huagang (袁華剛), aged 53, is our independent non-executive Director. Mr. Yuan was appointed as an independent non-executive Director in May 2023. Mr. Yuan is well versed in the relevant laws, rules and regulations of the capital market in China, and has long been engaged in M&A and restructuring and various innovative businesses and has engaged in and led many investment and investment banking projects with impact.

Mr. Yuan served in various positions at Guotai Junan Securities Co., Ltd. (a company listed on the Hong Kong Stock Exchange, stock code: 2611) from July 2000 to 2015, including executive director of investment banking department, managing director, deputy general manager and sponsor representative. He served as a director of EVE Energy Co., Ltd. (惠州億緯鋰能股份有限公司) (a company listed on the Shenzhen Stock Exchange, stock code: 300014) from October 2016 to October 2022. He served as the managing partner and a member of the Investment Decision-making Committee of Zhejiang United Investment Group* (浙江民營企業聯合投資股份有限公司) since June 2015.

Mr. Yuan has been an independent director of Shanghai Xinhua Media Co., Ltd. (上海新華傳媒股份有限公司) (a company listed on the Shanghai Stock Exchange, stock code: 600825) since October 2020. Mr. Yuan has been a director and the general manager of Pacific Shuanglin Bio-pharmacy Co., Ltd (派斯雙林生物製藥股份有限公司) (a company listed on the Shenzhen Stock Exchange, stock code: 000403) since March 2022.

Mr. Yuan obtained the PRC lawyer qualification (non-practicing) certificate in August 1998 and obtained the qualification for sponsor representative of the Securities Association of China in May 2009.

Mr. Yuan obtained his bachelor's degree in economics from Zhejiang University in July 1997 and a master's degree in business administration in banking and finance from the University of Macau in December 1999.

Ms. Liu Yuwen (劉毓文), aged 51, is our independent non-executive Director. Ms. Liu was appointed as an independent non-executive Director in March 2024. Ms. Liu has been the legal representative and founding partner of Suzhou Industrial Park Bohe Venture Investment Management Co., Ltd.* (蘇州工業園區薄荷創業投資管理有限公司) since August 2015, served as the executive deputy general manager, chairperson and general manager and executive director of Suzhou Industrial Park Biotech Development Co., Ltd.* (蘇州工業園區生物產業發展有限公司) (BioBAY) from December 2005 to July 2015, served as the chief representative of the Shanghai representative office of Perrigo International Inc. (美國百利高國際公司) from May 2003 to November 2005 (now known as Perrigo Trading (Shanghai) Co., Ltd.* (百利高貿易(上海)有限公司)).

Ms. Liu also worked as the new business development manager of Suzhou Capsugel Co., Ltd.* (蘇州膠囊有限公司) (“**Suzhou Capsugel**”), a Sino-US joint venture, from April 2000 to April 2003, a quality control and assurance manager of Suzhou Capsugel from May 1998 to April 2000, and a quality engineer of Suzhou Capsugel from July 1997 to April 1998.

Ms. Liu became a registered pharmacist in 2000, obtained a senior economist certificate from Jiangsu Provincial Department of Human Resources and Social Security in 2013 and obtained the qualification certificate of fund practitioner issued by the Asset Management Association of China in 2016.

Ms. Liu obtained the bachelor’s and master’s degree in pharmacy from the China Pharmaceutical University in 1994 and 1997, respectively, and a BI-Fudan master’s degree in business and administration offered in partnership by BI Norwegian Business School and Fudan University.

Mr. Siu, Paul Yu Hay (蕭耀熙), age 65, is a certified public accountant in Hong Kong and a chartered professional accountant in Ontario, Canada and he held multiple senior leadership positions at Deloitte from June 1996 to May 2023, including corporate development leader of Deloitte Asia Pacific, and various leadership roles in Deloitte China including chief operating officer and deputy chief executive officer, clients and industries leader, eastern region managing partner, eastern region audit leader, and audit partner. Mr. Siu has been serving as an independent director of Shanghai Jiaoda Onlly Co. Ltd (上海交大昂立股份有限公司) (a company listed on the main board of the Shanghai Stock Exchange, stock code: 600530) since 2023 and as an independent non-executive director of Tong Ren Tang Technologies Co. Ltd. (a company listed on the main board of the Hong Kong Stock Exchange, stock code: 1666).

Mr. Siu obtained his bachelor of mathematics degree from the University of Waterloo in Canada in May 1984. He was awarded the Shanghai Magnolia Award in October 2015 by Foreign Affairs Office of the Shanghai Municipal People’s Government (上海市人民政府外事辦公室).

Upon appointment, the Company will enter into a service contract with each Director.

Each of the above proposed independent non-executive Directors has confirmed that, as of the date of this announcement, (i) he/she meets the independence requirement in relation to each of the factors set out in Rules 3.13(1) to (8) of the Listing Rules; (ii) he/she has no past or present financial or other interests in the business of our Company or its subsidiaries or any connection with any core connected person (as defined under the Listing Rules) of our Company; and (iii) there are no other factors that may affect his/her independence at the time of his/her appointment. The Nomination Committee and the Board have assessed and consider that each of the proposed independent non-executive Directors meets the independence requirements set out in Rule 3.13 of the Listing Rules.

Each of the Director candidates of the sixth session of the Board has confirmed that, saved as disclosed above: (i) he/she does not hold any other position with the Company or any of its subsidiaries and has not been a director in any other listed companies during the past three years; (ii) he/she has no relationship with any other Directors, senior management, substantial or controlling shareholders of the Company; and (iii) as at the date of this announcement, he/she does not have any interest in the Shares of the Company within the meaning of Part XV of the SFO.

Each of the Director candidates of the sixth session of the Board has also confirmed that there is no other information in relation to his/her re-election or appointment that needs to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules, and there is no other matter in relation to his/her re-election or appointment that needs to be brought to the attention of the Hong Kong Stock Exchange and Shareholders.

If appointed, (1) each proposed executive Director of the sixth session of the Board will receive remuneration on based on their respective senior management positions within the Company, but will not receive remuneration in respect of his/her role as an executive Director; and (2) each proposed independent non-executive Director of the sixth session of the Board shall be entitled to RMB300,000 (tax inclusive) per annum. The remuneration of the proposed independent non-executive Directors was determined in accordance with the Company's remuneration policy and with reference to the level of remuneration paid by comparable companies, time commitment of the Directors, duties and responsibilities in the Group, their qualifications and experience. All Directors are entitled to travel expenses to attend relevant meetings and events of the Company and expenses incurred in the exercise of their duties in accordance with the Articles of Association. The Company will disclose the total remuneration received by the Directors in the annual report accordingly.

Pursuant to the Administrative Measures for Independent Directors of Listed Companies of the China Securities Regulatory Commission, the term of office of an independent director shall not exceed six consecutive years. As the 6-year term of office of Mr. Liu Kai Yu Kenneth as an independent non-executive Director of the Company is about to expire, he will not seek re-election to the sixth session of the Board and will retire from his position as independent non-executive Director, a member of the Remuneration and Evaluation Committee, a member of the Nomination Committee and the chairman of the Audit Committee. Mr. Liu Kai Yu Kenneth has confirmed that he has no disagreement with the Board and there are no other matters relating to his retirement that need to be brought to the attention of the Hong Kong Stock Exchange and Shareholders.

The Company will also hold an employee representative meeting to elect the employee Director of the sixth session of the Board in accordance with the Articles of Association in due course.

CIRCULAR

A circular containing, among other things, further details of the proposed re-election and appointment of Directors of the sixth session of the Board, together with the notice of the general meeting, will be published on the HKEXnews website (www.hkexnews.hk) and the Company's website (www.tigermedgrp.com) and will be provided to the Shareholders who have indicated their wishes to receive a printed copy in due course.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following terms shall have the following meanings:

“A Share(s)”	ordinary shares issued by the Company, with a nominal value of RMB1.00 each, which are subscribed for or credited as paid in Renminbi and are listed for trading on the Shenzhen Stock Exchange
“Articles of Association”	the articles of association of the Company, as amended from time to time
“Audit Committee”	the audit committee of the Board
“Board”	the board of Directors

“China” or “PRC”	the People’s Republic of China, which for the purpose of the announcement and for geographical reference only, excludes Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan
“Company Law”	the Company Law of the People’s Republic of China (《中華人民共和國公司法》)
“Company”, or “our Company”	Hangzhou Tigermed Consulting Co., Ltd. (杭州泰格醫藥科技股份有限公司), the A Shares of which are listed on the Shenzhen Stock Exchange (stock code: 300347) and the H Shares of which are listed on the Hong Kong Stock Exchange (stock code: 03347)
“Director(s)”	the director(s) of the Company or any one of them
“Group”	the Company and its wholly-owned subsidiaries
“H Share(s)”	ordinary share(s) in the share capital of our Company with nominal value of RMB1.00 each, which are listed on the Hong Kong Stock Exchange
“HK\$”	Hong Kong dollars and cents, both are the lawful currency of Hong Kong
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Hong Kong Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Listing Rules”	the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange (as amended from time to time)
“Nomination Committee”	the nomination committee of the Board
“Remuneration and Evaluation Committee”	The remuneration and evaluation committee of the Board
“RMB”	Renminbi, the lawful currency of the PRC

“SFO”	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)
“Share(s)”	comprising A Shares and H Shares
“Shareholder(s)”	holder(s) of Shares
“%”	percentage

By order of the Board
Hangzhou Tigermed Consulting Co., Ltd.
Ye Xiaoping
Chairman

Hong Kong, March 30, 2026

As at the date of this announcement, the executive Directors are Dr. Ye Xiaoping, Ms. Cao Xiaochun, Mr. Wu Hao and Mr. Wen Zengyu; the independent non-executive Directors are Mr. Liu Kai Yu Kenneth, Mr. Yuan Huagang and Ms. Liu Yuwen.

* *For identification purpose only*